Pharming Group Nv Stock Book Value Per Share
PHARM Stock | EUR 0.83 0.02 2.35% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Stock. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group stock.
Pharming |
Pharming Group NV Company Book Value Per Share Analysis
Pharming Group's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Pharming Group Book Value Per Share | 0.30 X |
Most of Pharming Group's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Competition |
In accordance with the recently published financial statements, the book value per share of Pharming Group NV is about 0.301 times. This is 117.71% lower than that of the Healthcare sector and 100.12% lower than that of the Biotechnology industry. The book value per share for all Netherlands stocks is 99.98% higher than that of the company.
Pharming Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.Pharming Group is currently under evaluation in book value per share category among its peers.
Pharming Fundamentals
Return On Equity | 0.17 | |||
Return On Asset | 0.0643 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 683.14 M | |||
Shares Outstanding | 652.41 M | |||
Shares Owned By Insiders | 1.97 % | |||
Shares Owned By Institutions | 16.43 % | |||
Price To Earning | 22.31 X | |||
Price To Book | 3.85 X | |||
Price To Sales | 3.57 X | |||
Revenue | 167.68 M | |||
Gross Profit | 177.73 M | |||
EBITDA | 41.22 M | |||
Net Income | 16 M | |||
Cash And Equivalents | 63.89 M | |||
Cash Per Share | 0.10 X | |||
Total Debt | 122.65 M | |||
Debt To Equity | 84.60 % | |||
Current Ratio | 1.53 X | |||
Book Value Per Share | 0.30 X | |||
Cash Flow From Operations | 37.84 M | |||
Earnings Per Share | 0.04 X | |||
Target Price | 8.02 | |||
Number Of Employees | 277 | |||
Beta | 0.98 | |||
Market Capitalization | 811.08 M | |||
Total Asset | 350.55 M | |||
Z Score | 3.6 | |||
Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Information and Resources on Investing in Pharming Stock
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.